Share This Page
Suppliers and packagers for docetaxel
✉ Email this page to a colleague
docetaxel
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 201195 | NDA | Accord Healthcare Inc. | 16729-267-63 | 1 VIAL, MULTI-DOSE in 1 CARTON (16729-267-63) / 1 mL in 1 VIAL, MULTI-DOSE | 2013-05-30 |
| Accord Hlthcare | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 201195 | NDA | Accord Healthcare Inc. | 16729-267-64 | 1 VIAL, MULTI-DOSE in 1 CARTON (16729-267-64) / 4 mL in 1 VIAL, MULTI-DOSE | 2013-05-30 |
| Accord Hlthcare | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 201195 | NDA | Accord Healthcare Inc. | 16729-267-65 | 1 VIAL, MULTI-DOSE in 1 CARTON (16729-267-65) / 8 mL in 1 VIAL, MULTI-DOSE | 2013-05-30 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: DOCETAXEL
Introduction
Docetaxel, a chemotherapeutic agent primarily used in the treatment of various cancers, including breast, lung, prostate, and stomach cancers, has gained significant prominence in oncology. As a semi-synthetic taxane derived from the Pacific yew tree (Taxus brevifolia), its production involves complex extraction and synthesis processes, leading to a concentrated global supplier network. For pharmaceutical companies, healthcare providers, and distributors, understanding the landscape of docetaxel suppliers is critical for ensuring consistent supply, quality standards, and cost efficiency. This article offers a comprehensive overview of leading suppliers, their manufacturing capabilities, regulatory compliance, and strategic positioning within the global market.
Global Market Overview of Docetaxel Suppliers
The supply of docetaxel is characterized by a mix of originations, including both originator (brand) and generic manufacturers. The prominent players span established pharmaceutical giants with proprietary manufacturing processes, as well as generic firms that have developed cost-effective production methods post-patent expiration.
The initial patent for Taxotere™, the original branded formulation of docetaxel developed by Sanofi, expired in many jurisdictions, leading to an influx of generic manufacturers entering the market. Consequently, the supply landscape has evolved, expanding supply options while raising concerns about quality assurance and regulatory compliance.
Major Suppliers of Docetaxel
1. Sanofi (Brand: Taxotere)
As the originator of docetaxel, Sanofi remains a leading supplier of the branded formulation, Taxotere. Its manufacturing facilities adhere to stringent quality standards, including Good Manufacturing Practices (GMP) and regulatory approvals from agencies such as the FDA, EMA, and other national authorities. Although Sanofi continues to produce the original drug, the expiration of patent rights has opened avenues for generic competition.
2. Teva Pharmaceutical Industries
Teva, a global pharmaceutical leader specializing in generics, is a key supplier of bioequivalent docetaxel formulations. Teva's manufacturing capacities span multiple countries, notably Israel, India, and Europe. They focus on maintaining high-quality standards aligned with international regulatory requirements, offering cost-competitive options to global markets.
3. Pfizer
Although Pfizer's primary involvement in oncology drugs primarily involves different compounds, it supplies certain oncology injectables, including generic docetaxel through licensing arrangements. Their extensive global distribution network makes them a significant supplier, particularly in North America and Europe.
4. Sandoz (Novartis)
Sandoz, Novartis’ generics arm, produces a wide range of chemotherapeutic agents, including docetaxel. Their manufacturing facilities in Europe and Asia are compliant with GMP standards and serve multiple markets, emphasizing high-quality excipient and active pharmaceutical ingredient (API) production.
5. Jiangsu Hengrui Medicine Co., Ltd.
This Chinese pharmaceutical firm has established a prominent position in the Asian market, producing both branded and generic docetaxel. Their manufacturing facilities are certified under China's GMP standards and increasingly aim to meet international quality benchmarks to expand global exports.
6. Intas Pharmaceuticals
Based in India, Intas manufactures generic docetaxel, leveraging India’s robust pharmaceutical manufacturing sector. Their facilities are certified by the World Health Organization (WHO) and other international agencies, serving emerging markets and export-focused orders.
7. Hospira (Part of Pfizer now)
Hospira was historically a key producer of sterile injectables, including docetaxel. Following Pfizer's acquisition, Hospira’s manufacturing capabilities are integrated into Pfizer's global supply chain, contributing significantly to availability in North America and certain European markets.
8. Other Regional Suppliers
Additional regional suppliers include firms such as Cadila Healthcare (India), Zydus Cadila, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries, all contributing to the global supply of generic docetaxel. These companies have increased their production capacity to cater to growing demand in local and export markets.
Qualitative Factors Influencing Supplier Choice
- Regulatory Certification: Suppliers with approvals from major agencies (FDA, EMA, PMDA, TGA) are preferred for international markets.
- Manufacturing Quality: GMP compliance and rigorous quality control processes ensure product safety and efficacy.
- Cost and Supply Stability: Competitive pricing combined with reliable supply chain logistics is essential for procurement strategies.
- Technological Capabilities: Advanced extraction, synthesis, and formulation technologies influence reliability and scalability.
- Global Reach: Suppliers with extensive distribution networks can better serve multinational corporations and regional markets.
Regulatory and Quality Considerations
The sourcing of docetaxel necessitates careful due diligence with regard to regulatory compliance. Regulatory agencies scrutinize manufacturing processes, API sourcing, and stability data. Additionally, companies often verify suppliers’ Good Manufacturing Practices (GMP) certificates and ensure adherence to pharmacopoeial standards (e.g., USP, EP, JP).
The global landscape has seen increased emphasis on supply chain transparency, particularly post-pandemic, with regulatory bodies emphasizing risk mitigation for active pharmaceutical ingredient (API) shortages.
Supply Chain Challenges and Opportunities
The primary challenges in sourcing docetaxel include geopolitical risks, manufacturing capacity limitations, and periodic quality concerns. The semi-synthetic nature of the drug, which involves complex extraction from natural sources, fosters reliance on a limited number of API producers, heightening vulnerability to supply disruptions.
Conversely, manufacturing innovations such as continuous processing, synthetic route optimization, and diversification of sourcing have the potential to improve supply stability. The increasing presence of Chinese and Indian manufacturers underscores opportunities to lower costs and expand access but necessitates rigorous validation and quality control.
Emerging Trends and Future Outlook
The market is witnessing a trend toward biosimilar versions of taxanes, which may eventually impact demand dynamics for traditional docetaxel formulations. Additionally, technological advancements in synthetic biology and manufacturing could revolutionize how active ingredients are produced, easing supply constraints.
Global regulatory harmonization efforts, especially through the International Council for Harmonisation (ICH), aim to streamline approval processes, encouraging new entrants and diversified manufacturing sites, thereby enhancing resilience.
Key Takeaways
- Diverse Supplier Base: Major global players include Sanofi (brand), Teva, Sandoz, Jiangsu Hengrui, and Indian generics such as Intas and Zydus.
- Regulatory Compliance Essential: Suppliers must uphold GMP standards and obtain certifications from key health authorities to meet international procurement requirements.
- Supply Chain Risks: Dependency on limited sources of APIs and geopolitical factors necessitates diversified sourcing strategies.
- Quality Assurance Priority: Consistent quality and regulatory adherence are non-negotiable, especially given the drug’s critical therapeutic role.
- Market Evolution: Technological innovations and biosimilar developments may reshape the supplier landscape in the coming decade.
FAQs
1. Who are the leading global suppliers of docetaxel?
Major suppliers include Sanofi (brand: Taxotere), Teva, Sandoz (Novartis), Jiangsu Hengrui, and Indian manufacturers like Intas and Zydus. These companies offer both branded and generic formulations worldwide.
2. How do I verify the quality of a docetaxel supplier?
Verify GMP certification, regulatory approvals (FDA, EMA, PMDA), batch testing reports, and compliance with pharmacopoeial standards. Third-party audits and supplier audits further guarantee quality.
3. What are the supply risks associated with sourcing docetaxel?
Risks include API shortages, geopolitical instability, manufacturing disruptions, and regulatory changes. Diversifying suppliers mitigates dependency and supply interruptions.
4. Are biosimilars or generic versions of docetaxel available?
Yes, multiple generic versions are available globally, with biosimilar taxanes emerging as future competitors, potentially impacting traditional docetaxel demand.
5. How is the global supply chain evolving for docetaxel?
The supply chain is becoming more diversified with increased manufacturing capacity in China, India, and Eastern Europe, alongside heightened regulatory scrutiny and quality assurance measures.
References:
[1] Market data on taxane pharmaceuticals, Global Industry Analysts, 2022.
[2] Sanofi official website on Taxotere.
[3] World Health Organization (WHO) reports on pharmaceutical manufacturing standards.
[4] Industry analyses from IQVIA and EvaluatePharma.
[5] Regulatory agency publications (FDA, EMA, PMDA) on pharmaceutical manufacturing and approval standards.
More… ↓
